Figure 1.
Simplified mechanisms of action of targeted therapies for treatment of soft tissue sarcoma. *Indicates that medication is FDA approved for treatment of certain soft tissue sarcoma subtypes. Key: Platelet derived growth factor receptor (PDGFR); vascular endothelial growth factor receptor (VEGFR); stem cell growth factor receptor (c-kit); Hepatocyte Growth Factor Receptor (c-Met); Anaplastic Lymphoma Kinase (ALK); cyclin dependent kinase (CDK); colony stimulating factor 1 (CSF1); enhancer of zeste homolog 2 (EZH2); retinoblastoma (RB).